Complexa Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Complexa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11172
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Complexa Inc (Complexa) is a biopharmaceutical company that develops endogenous human cell signalling treatments for fibrosis and inflammation related diseases. The company’s lead product candidate products includes CXA-10 is an endogenous nitro fatty acid that modulates the human body’s main fibrosis, inflammatory and oxidative stress pathways. It utilizes endogenous and derivative nitro and keto fatty-acid cell signaling agents such as nuclear factor, hemeoxygenase-1, and heat shock factor. The company’s CXA-10 is developed in both oral and formulations for chronic kidney injury and orphan indications. It has operations in Radnor and Pittsburgh, the US. Complexa is headquartered in Chester, Pennsylvania, the US.

Complexa Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complexa Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Complexa Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Complexa Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Complexa Raises USD62 Million in Series C Financing 10
Complexa Raises USD1 Million in Venture Financing 12
Complexa Raises USD1 Million in Financing Round 13
Complexa Raises USD4 Million in Venture Financing 14
Complexa Raises USD13 Million in Series B Financing 15
Complexa Secures Seed Funding from Innovation Works 16
Complexa Raises USD3.2 Million in Venture Financing 17
Complexa Raises US$0.2 Million In Venture Financing 18
Complexa Raises US$2 Million In Venture Financing 19
Complexa Raises US$1.4 Million In Venture Financing 20
Complexa Inc – Key Competitors 21
Complexa Inc – Key Employees 22
Complexa Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Product News 24
05/14/2018: Complexa Appoints Francisco D. Salva Chief Executive Officer and President 24
Clinical Trials 25
Jun 01, 2018: First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Complexa Inc, Pharmaceuticals & Healthcare, Key Facts 2
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complexa Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complexa Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Complexa Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Complexa Raises USD62 Million in Series C Financing 10
Complexa Raises USD1 Million in Venture Financing 12
Complexa Raises USD1 Million in Financing Round 13
Complexa Raises USD4 Million in Venture Financing 14
Complexa Raises USD13 Million in Series B Financing 15
Complexa Secures Seed Funding from Innovation Works 16
Complexa Raises USD3.2 Million in Venture Financing 17
Complexa Raises US$0.2 Million In Venture Financing 18
Complexa Raises US$2 Million In Venture Financing 19
Complexa Raises US$1.4 Million In Venture Financing 20
Complexa Inc, Key Competitors 21
Complexa Inc, Key Employees 22

List of Figures
Complexa Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Complexa Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Complexa Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Complexa Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • bioLytical Laboratories Inc:製品パイプライン分析
    Summary bioLytical Laboratories Inc (bioLytical) is a medical device company that develops and manufactures HIV diagnostic products. The company offers products such as insti HIV-1/HIV-2 antibody test and insti HIV-1/HIV-2 test controls. Its product line provides test results that translates into a …
  • Fukuda Denshi Co Ltd (6960):医療機器:M&Aディール及び事業提携情報
    Summary Fukuda Denshi Co Ltd (Fukuda Denshi) is a medical device company, which develops, manufactures, and commercializes medical equipment including cardiology, patient monitoring, vascular screening and ultrasound systems. The company’s product portfolio includes electrocardiographs, stress tests …
  • The Talbots, Inc.:企業の戦略的SWOT分析
    The Talbots, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報
    Summary Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and …
  • Sumitomo Realty & Development Co., Ltd.:企業の戦略・SWOT・財務情報
    Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Realty & Development Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Almirall S.A.:企業の戦略・SWOT・財務分析
    Almirall S.A. - Strategy, SWOT and Corporate Finance Report Summary Almirall S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • X4 Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary X4 Pharmaceuticals Inc (X4 Pharma) is a clinical stage biotechnology company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiencies. It …
  • Vermilion Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Vermilion Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Vermilion Energy Inc (Vermilion) is an oil and gas company that offers exploration and production services. The company is an oil and gas producer in Alberta. It offers production programs focus …
  • CiMaas BV:製薬・医療:M&Aディール及び事業提携情報
    Summary CiMaas BV (CiMaas) develops cellular immunotherapies (vaccines) for the treatment of cancer. Its pipeline cellular therapeutic products include CIM101, a dendritic cell vaccine being developed using its proprietary maturation technology for the treatment of lung cancer; and CIM201, a haploid …
  • Amplia Therapeutics Ltd (ATX):製薬・医療:M&Aディール及び事業提携情報
    Summary Amplia Therapeutics Ltd (Amplia Therapeutics), formerly Innate Therapeutics Ltd, is a pharmaceutical company with focus on the development of focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. Its lead drug candidate, AMP945, is a small molecule targeting focal …
  • Woodside Petroleum Ltd (WPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Woodside Petroleum Ltd (Woodside) is an independent oil and gas company that explores, develops, produces and supplies energy. It explores and produces oil and gas from a portfolio of facilities in association with some of the world’s major oil and gas companies. The company operates liquefi …
  • BASF India Ltd (BASF):企業の財務・戦略的SWOT分析
    Summary BASF India Ltd (BASF) a subsidiary of BASF SE is a chemical company that manufactures and distributes specialty chemicals, performance products, plastics and crop protection products. The company’s chemical products include intermediates, monomers and petrochemicals. Its performance products …
  • Daewoo Shipbuilding & Marine Engineering Co Ltd:企業の戦略・SWOT・財務分析
    Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • SMART Medical Systems Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Smart Medical Systems Ltd (Smart) is a medical device company that develops and manufactures gastroenterology and GI endoscopy devices. The company offers products such as inflation systems, platform, naviaid ABC, G-eye, naviaid AB, future naviaid products, controlled withdrawal, and others. …
  • Visteon Corporation:企業の戦略・SWOT・財務情報
    Visteon Corporation - Strategy, SWOT and Corporate Finance Report Summary Visteon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Petkim Petrokimya Holding AS (PETKM):企業の財務・戦略的SWOT分析
    Summary Petkim Petrokimya Holding AS (Petkim Petrokimya), a subsidiary of State Oil Company of the Azerbaijan Republic, is a chemical company. Its products portfolio includes propylene, acrylonitrile, ethylene, polyvinyl chloride, aromatics, polypropylene, sodium hydroxide, diethylene glycol, polyme …
  • Xeikon N.V.:企業の戦略的SWOT分析
    Xeikon N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Beijer Ref Ab:企業のM&A・事業提携・投資動向
    Beijer Ref Ab - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Beijer Ref Ab Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Nayara Energy Ltd.:企業の戦略・SWOT・財務分析
    Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nayara Energy Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Royal Mail plc (RMG):企業の財務・戦略的SWOT分析
    Royal Mail plc (RMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆